(2) Criteria developed under subsection (1) of this section must include:
(a) Prescribing a high volume of opioids or opiates classified in schedules II and III;
(b) Prescribing an above-average amount of doses of opioids or opiates classified in schedules II and III to a high number of patients; and
(c) Simultaneously prescribing opioids or opiates classified in schedules II and III with other drugs classified in schedules II and III.
(3) In developing the criteria developed under subsection (1) of this section, the authority must take into consideration the total quantity and volume of opioids and opiates classified in schedules II and III prescribed by each practitioner.
(4) The subcommittee may review, through the use of prescription monitoring information that does not identify a patient, a practitioner’s prescribing history for the three years immediately preceding the date of the review to determine whether a practitioner meets the criteria developed under subsection (1) of this section.
(5) After performing the review described in subsection (4) of this section, the subcommittee may direct the authority to provide to a practitioner who meets the criteria developed under subsection (1) of this section educational information about prescribing opioids and opiates, as determined appropriate by the authority.
(6)(a) For the purposes of evaluating prescriptions made by practitioners of opioids and opiates and other controlled substances, the subcommittee may direct the authority to compare the prescriptions described in this paragraph between similarly situated practitioners and to provide the comparative information to practitioners who meet criteria established by the subcommittee.
(b) The subcommittee may adopt rules to carry out this subsection, including rules to establish criteria to determine to which practitioners to provide the information described in this subsection.
(7) Prescription monitoring information used for purposes of this section and the data created through the use of prescription monitoring information pursuant to this section:
(a) Are confidential and not subject to public disclosure under ORS 192.311 to 192.478; and
(b) Are not admissible as evidence in a civil or criminal proceeding. [2017 c.683 §19; 2019 c.583 §20]